Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of using an investigational procedure (fecal
microbiota transplantation [FMT]) in treating patients with severe acute gut
graft-versus-host-disease. The purpose of a fecal microbiota transplantation is to use feces
from a healthy human donor to replace the abnormal gut bacteria in the recipient. One of the
side effects of a stem cell transplant is the development of graft-versus-host disease (GvHD)
in several organs including gut. GvHD is caused by the donated bone marrow or peripheral
blood cells recognizing the recipient's body as foreign and attacking it. Acute gut GvHD is
one of the leading causes of death after transplant. Recently, studies have shown that
patients with reduced intestinal bacterial diversity in their stool during acute gut GvHD
have higher overall mortality rates. The information learned from this study may offer FMT as
a promising therapy for the treatment of severe acute gut graft-versus-host-disease.